CN107446051B9 - 靶向cd19的嵌合抗原受体及其用途 - Google Patents
靶向cd19的嵌合抗原受体及其用途 Download PDFInfo
- Publication number
- CN107446051B9 CN107446051B9 CN201610377871.4A CN201610377871A CN107446051B9 CN 107446051 B9 CN107446051 B9 CN 107446051B9 CN 201610377871 A CN201610377871 A CN 201610377871A CN 107446051 B9 CN107446051 B9 CN 107446051B9
- Authority
- CN
- China
- Prior art keywords
- cell
- seq
- sequence
- people
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Abstract
Description
Claims (15)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910012631.8A CN109503721B (zh) | 2016-05-31 | 2016-05-31 | 靶向cd19的嵌合抗原受体及其用途 |
CN201610377871.4A CN107446051B9 (zh) | 2016-05-31 | 2016-05-31 | 靶向cd19的嵌合抗原受体及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610377871.4A CN107446051B9 (zh) | 2016-05-31 | 2016-05-31 | 靶向cd19的嵌合抗原受体及其用途 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910012631.8A Division CN109503721B (zh) | 2016-05-31 | 2016-05-31 | 靶向cd19的嵌合抗原受体及其用途 |
Publications (3)
Publication Number | Publication Date |
---|---|
CN107446051A CN107446051A (zh) | 2017-12-08 |
CN107446051B CN107446051B (zh) | 2019-01-11 |
CN107446051B9 true CN107446051B9 (zh) | 2019-02-22 |
Family
ID=60485419
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910012631.8A Active CN109503721B (zh) | 2016-05-31 | 2016-05-31 | 靶向cd19的嵌合抗原受体及其用途 |
CN201610377871.4A Active CN107446051B9 (zh) | 2016-05-31 | 2016-05-31 | 靶向cd19的嵌合抗原受体及其用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910012631.8A Active CN109503721B (zh) | 2016-05-31 | 2016-05-31 | 靶向cd19的嵌合抗原受体及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN109503721B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019114751A1 (zh) * | 2017-12-12 | 2019-06-20 | 科济生物医药(上海)有限公司 | 免疫效应细胞和辐射联用治疗肿瘤 |
CN108101994B (zh) * | 2018-01-04 | 2020-09-15 | 广东万海细胞生物科技有限公司 | 抗cd19抗体及其应用 |
CN108504668B (zh) * | 2018-05-23 | 2024-02-20 | 上海恒润达生生物科技股份有限公司 | 靶向cd19和cd22嵌合抗原受体及其用途 |
CN108864310A (zh) * | 2018-07-31 | 2018-11-23 | 苏州茂行生物科技有限公司 | 一种靶向间皮素并携带PD-Ll阻断剂的CAR-T细胞的构建及其应用 |
CN110079504A (zh) * | 2019-05-06 | 2019-08-02 | 山东大学第二医院 | 一种含有不稳定结构域的car-t细胞及其制备方法和调节car-t细胞功能方法 |
CN110317277A (zh) * | 2019-07-10 | 2019-10-11 | 杭州普科亭生物医药有限公司 | 嵌合抗原受体及其应用 |
KR20230012571A (ko) * | 2020-05-18 | 2023-01-26 | 크라제 메디컬 씨오 리미티드 | 면역 이펙터 세포를 이용한 종양 치료 |
CN113621068B (zh) * | 2021-10-11 | 2022-01-07 | 上海恒润达生生物科技股份有限公司 | 一种特异性结合cd276的抗体或其抗原结合片段及其制备方法和应用 |
CN114606263B (zh) * | 2022-05-11 | 2022-09-06 | 上海优替济生生物医药有限公司 | 分离的核酸分子及其用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104788573A (zh) * | 2015-05-08 | 2015-07-22 | 中国医学科学院血液病医院(血液学研究所) | 嵌合抗原受体hCD19scFv-CD8α-CD28-CD3ζ及其用途 |
CN105418765A (zh) * | 2014-08-26 | 2016-03-23 | 西比曼生物科技(上海)有限公司 | Cd19靶向性的嵌合抗原受体和nkt细胞及其制法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002077029A2 (en) * | 2000-11-07 | 2002-10-03 | City Of Hope | Cd19-specific redirected immune cells |
MXPA06009253A (es) * | 2004-02-16 | 2007-04-18 | Micromet Ag | Moleculas de enlace menos inmunogenicas. |
CN1749277A (zh) * | 2004-09-14 | 2006-03-22 | 北京迪威华宇生物技术有限公司 | 热休克蛋白65-人sars冠状病毒表位抗原重组融合蛋白(hsp65-sars/3cl161-264) |
CN104087607B (zh) * | 2013-04-01 | 2017-06-20 | 科济生物医药(上海)有限公司 | 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞 |
FI3546572T3 (fi) * | 2013-05-13 | 2024-05-06 | Cellectis | Cd19-spesifinen kimeerinen antigeenireseptori ja sen käyttötapoja |
ES2688035T3 (es) * | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
-
2016
- 2016-05-31 CN CN201910012631.8A patent/CN109503721B/zh active Active
- 2016-05-31 CN CN201610377871.4A patent/CN107446051B9/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105418765A (zh) * | 2014-08-26 | 2016-03-23 | 西比曼生物科技(上海)有限公司 | Cd19靶向性的嵌合抗原受体和nkt细胞及其制法和应用 |
CN104788573A (zh) * | 2015-05-08 | 2015-07-22 | 中国医学科学院血液病医院(血液学研究所) | 嵌合抗原受体hCD19scFv-CD8α-CD28-CD3ζ及其用途 |
Non-Patent Citations (1)
Title |
---|
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia;Shannon L.Maude et al.;《BLOOD》;20150114;第125卷(第26期);4017-4023 * |
Also Published As
Publication number | Publication date |
---|---|
CN109503721B (zh) | 2023-03-07 |
CN107446051B (zh) | 2019-01-11 |
CN107446051A (zh) | 2017-12-08 |
CN109503721A (zh) | 2019-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107446051B9 (zh) | 靶向cd19的嵌合抗原受体及其用途 | |
CN105949324B (zh) | 靶向gpc3的嵌合抗原受体及其用途 | |
CN108504668A (zh) | 靶向cd19和cd22嵌合抗原受体及其用途 | |
CN108018299B (zh) | 靶向bcma的嵌合抗原受体及其用途 | |
CN108728459A (zh) | 靶向cd19的嵌合抗原受体并联合表达il-15的方法和用途 | |
CN108070607A (zh) | 靶向CD19-41BB-tEGFR的嵌合抗原受体及其用途 | |
CN109320615A (zh) | 靶向新型bcma的嵌合抗原受体及其用途 | |
CN107964549A (zh) | 靶向cd22的嵌合抗原受体及其用途 | |
CN108004259A (zh) | 靶向b细胞成熟抗原的嵌合抗原受体及其用途 | |
CN107868792B (zh) | 靶向cd123的嵌合抗原受体及其用途 | |
CN107841506A (zh) | 靶向间皮素的嵌合抗原受体及其用途 | |
CN108864286A (zh) | 靶向cd19的嵌合抗原受体及联合表达抗pd1抗体可变区的方法和及其用途 | |
CN108330133A (zh) | 靶向cd19嵌合抗原受体并对其双重修饰的方法及其用途 | |
CN108441505A (zh) | 一种靶向ror1的嵌合抗原受体及其用途 | |
KR20240046644A (ko) | 고형암을 위한 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포 | |
CN108070608A (zh) | 靶向CD19-CD28-tEGFR的嵌合抗原受体及其用途 | |
CN108715616A (zh) | 靶向人源化间皮素的嵌合抗原受体方法和用途 | |
CN109423495A (zh) | 一种双靶向嵌合抗原受体及其用途 | |
CN108866088A (zh) | 靶向cll-1嵌合抗原受体及其用途 | |
CN108456247A (zh) | 靶向ny-eso-1的t细胞受体及其用途 | |
CN108239623A (zh) | 一种混合cart细胞的制备方法和应用 | |
CN108285489A (zh) | 靶向BCMA-BBz-tEGFR的嵌合抗原受体及其用途 | |
CN108728460A (zh) | 靶向gd2的嵌合抗原受体及其用途 | |
CN109306012A (zh) | 一种靶向鼠cd19的嵌合抗原受体及其用途 | |
CN109504698A (zh) | 一种靶向全人源化mesothelin的嵌合抗原受体的方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CI03 | Correction of invention patent |
Correction item: Claims Correct: Zheng Que False: Cuo Wu Number: 02-02 Page: Quan Wen Volume: 35 |
|
CI03 | Correction of invention patent | ||
CB03 | Change of inventor or designer information |
Inventor after: He Feng Inventor after: Jin Tao Inventor after: Shi Zixiao Inventor before: Li Qijing Inventor before: Jin Tao Inventor before: He Feng Inventor before: Shi Zixiao |
|
CB03 | Change of inventor or designer information | ||
CP03 | Change of name, title or address |
Address after: 201210 block D, 1st floor, building 1, Lane 1238, Zhangjiang Road, China (Shanghai) free trade zone, Pudong New Area, Shanghai Patentee after: Shanghai Hengrun Dasheng Biotechnology Co.,Ltd. Address before: 201210 8th floor, building 1, Lane 1238, Zhangjiang Road, Pudong New Area, Shanghai Patentee before: SHANGHAI HRAIN BIOTECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address |